Vertex advances program targeting alpha-1 antitrypsin deficiency

Boston--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) today announced the advancement of its investigational program targeting alpha-1 antitrypsin deficiency (aatd), a rare, genetic disease characterized by a protein folding defect that can lead to liver and lung disease. vertex announced that the u.s. food and drug administration (fda) has cleared the investigational new drug (ind) application for vx-634 enabling the company to initiate a first-in-human clinical trial for
VRTX Ratings Summary
VRTX Quant Ranking